Public Health

The FDA approved ensitrelvir (Xocova) for post-exposure prophylaxis of COVID-19 in adults and adolescents aged 12 years and older following contact with an individual with COVID-19.

A population-based study examined the associations between short- and intermediate-term environmental exposures and migraine-related encounters.

The FDA approved cefepime and zidebactam (Zaynich, Wockhardt), a novel intravenous antibiotic, for adults with complicated urinary tract infections, including pyelonephritis, caused by susceptible...

ACOG’s 2026 maternal immunization schedule outlines vaccine recommendations before, during, and after pregnancy, including influenza, COVID-19, Tdap, and RSV vaccination.

FDA approval gives physicians the first authorized treatment option for adults with chronic hepatitis delta virus infection.

In the phase 3 RASolute 302 trial, daraxonrasib improved overall survival and progression-free survival vs chemotherapy in patients with second-line metastatic pancreatic adenocarcinoma.

In a retrospective national VA cohort of nearly 1 million Veterans, tobacco smoking duration criteria identified more screening-eligible patients and fewer missed lung cancer diagnoses than pack-year...

In a phase 3 trial, ensitrelvir reduced symptomatic COVID-19 after household exposure when started within 72 hours.

The FDA approved Baxfendy as an adjunctive treatment to lower blood pressure in adults with hypertension not adequately controlled on other antihypertensive medications.

On May 22, 2026, the FDA approved datopotamab deruxtecan-dlnk for adults with unresectable or metastatic triple-negative breast cancer who are not candidates for PD-1/PD-L1 inhibitor therapy, based on...